Louise Campbell and Alina Allen discuss the psychological and practical aspects of treating patients (particularly those with cirrhosis) who know they are at risk of imminent progression, while Roger Green asks whether this kind of predictive power might drive Compassionate Use trials for agents that have not been approved yet. The question, “Who will be the Larry Kramer of NASH?” comes into this discussion as well.
